Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103(+) conventional dendritic cells

BACKGROUND: Type 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103(+) cDC1s in mice, CD141(+) cDC1s in humans) are linked with improved tumor control, yet the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Yifan, Slone, Natalie, Chrisikos, Taylor T, Kyrysyuk, Oleksandr, Babcock, Rachel L, Medik, Yusra B, Li, Haiyan S, Kleinerman, Eugenie S, Watowich, Stephanie S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254126/
https://www.ncbi.nlm.nih.gov/pubmed/32273347
http://dx.doi.org/10.1136/jitc-2019-000474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254126/
https://www.ncbi.nlm.nih.gov/pubmed/32273347
http://dx.doi.org/10.1136/jitc-2019-000474

Ejemplares similares